JP2015521607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521607A5 JP2015521607A5 JP2015517621A JP2015517621A JP2015521607A5 JP 2015521607 A5 JP2015521607 A5 JP 2015521607A5 JP 2015517621 A JP2015517621 A JP 2015517621A JP 2015517621 A JP2015517621 A JP 2015517621A JP 2015521607 A5 JP2015521607 A5 JP 2015521607A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- antibody
- administered
- treatment
- morphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/061618 WO2013189516A1 (en) | 2012-06-18 | 2012-06-18 | Method for treating a gd2 positive cancer |
| EPPCT/EP2012/061618 | 2012-06-18 | ||
| PCT/EP2012/064970 WO2013189554A1 (en) | 2012-06-18 | 2012-07-31 | Method for treating a gd2 positive cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521607A JP2015521607A (ja) | 2015-07-30 |
| JP2015521607A5 true JP2015521607A5 (enExample) | 2015-09-17 |
| JP6283665B2 JP6283665B2 (ja) | 2018-02-21 |
Family
ID=46317406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015517621A Active JP6283665B2 (ja) | 2012-06-18 | 2012-07-31 | Ｇｄ２陽性癌を治療するための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10294305B2 (enExample) |
| JP (1) | JP6283665B2 (enExample) |
| KR (1) | KR101927118B1 (enExample) |
| CN (1) | CN104487088A (enExample) |
| AP (1) | AP2014008129A0 (enExample) |
| AU (1) | AU2012383254B2 (enExample) |
| BR (1) | BR112014031806A8 (enExample) |
| CA (1) | CA2876529C (enExample) |
| EA (1) | EA038188B1 (enExample) |
| HK (1) | HK1203375A1 (enExample) |
| IL (1) | IL235696A0 (enExample) |
| MX (1) | MX377157B (enExample) |
| SG (2) | SG10201610532QA (enExample) |
| WO (2) | WO2013189516A1 (enExample) |
| ZA (1) | ZA201407961B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| JP6693873B2 (ja) | 2013-11-21 | 2020-05-13 | アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ | Ｇｄ２陽性がんを処置するための製剤および方法 |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| CA2950602C (en) * | 2014-06-04 | 2021-07-20 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside gd2 |
| US10329323B2 (en) | 2014-07-25 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method for purifying antibodies using PBS |
| WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR20200059249A (ko) * | 2017-09-21 | 2020-05-28 | 유엠씨 우트레크트 홀딩 비.브이. | 신경아세포종의 치료를 위한 항-gd2 항체 |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| WO2020165402A1 (en) | 2019-02-14 | 2020-08-20 | Westfälische Wilhelms-Universität Münster | Gd2-upregulation by ezh2 inhibition in cancer therapy |
| EP3968971A1 (en) | 2019-05-17 | 2022-03-23 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| WO2021020564A1 (ja) * | 2019-08-01 | 2021-02-04 | 国立大学法人三重大学 | Ｇｄ２結合性分子 |
| US20220411535A1 (en) * | 2019-11-26 | 2022-12-29 | University Of Utah Research Foundation | Compositions and methods for upregulating hla class i on tumor cells |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| CN115835884A (zh) | 2020-07-06 | 2023-03-21 | 尤萨制药(英国)有限公司 | 治疗gd2阳性癌症的方法 |
| JP2024524527A (ja) * | 2021-07-05 | 2024-07-05 | トリオン リサーチ ゲーエムベーハー | がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 |
| EP4116330A1 (en) * | 2021-07-05 | 2023-01-11 | Trion Research GmbH | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| EP4194471A1 (en) * | 2021-12-10 | 2023-06-14 | Y-Mabs Therapeutics, Inc. | Anti-gd2 administration regimen |
| GB202307103D0 (en) | 2023-05-12 | 2023-06-28 | Prinses Maxima Centrum Voor Kinderoncologie B V | Method for detecting a GD2 positive cancer |
| WO2025257810A1 (en) * | 2024-06-14 | 2025-12-18 | Singh Biotechnology, Llc | Suppression of neurodegenerative diseases by single domain antibody |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| JP4731793B2 (ja) * | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| JP4494977B2 (ja) * | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 |
| ATE443724T1 (de) | 2004-01-22 | 2009-10-15 | Merck Patent Gmbh | Antikrebs-antikörper mit reduzierter komplementfixierung |
| WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| CN102164962B (zh) | 2008-06-30 | 2014-05-28 | 诺福泰克公司 | 抗gd2抗体和方法及其相关应用 |
| KR101834026B1 (ko) * | 2010-06-19 | 2018-03-02 | 메모리얼 슬로안-케터링 캔서 센터 | 항-ｇｄ2 항체 |
| US8435972B2 (en) * | 2010-09-02 | 2013-05-07 | Emory University | Method for the treatment of central nervous system cancers and compositions related thereto |
| HUE044633T2 (hu) | 2011-10-27 | 2019-11-28 | Genmab As | Heterodimer fehérjék elõállítása |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| US9840566B2 (en) * | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| JP6693873B2 (ja) | 2013-11-21 | 2020-05-13 | アペイロン・バイオロジックス・アクチェンゲゼルシャフトＡＰＥＩＲＯＮ Ｂｉｏｌｏｇｉｃｓ ＡＧ | Ｇｄ２陽性がんを処置するための製剤および方法 |
-
2012
- 2012-06-18 WO PCT/EP2012/061618 patent/WO2013189516A1/en not_active Ceased
- 2012-07-31 CN CN201280074061.1A patent/CN104487088A/zh active Pending
- 2012-07-31 CA CA2876529A patent/CA2876529C/en active Active
- 2012-07-31 EA EA201500019A patent/EA038188B1/ru unknown
- 2012-07-31 AP AP2014008129A patent/AP2014008129A0/xx unknown
- 2012-07-31 MX MX2014013858A patent/MX377157B/es active IP Right Grant
- 2012-07-31 KR KR1020147033790A patent/KR101927118B1/ko active Active
- 2012-07-31 HK HK15103941.7A patent/HK1203375A1/xx unknown
- 2012-07-31 SG SG10201610532QA patent/SG10201610532QA/en unknown
- 2012-07-31 SG SG11201408487WA patent/SG11201408487WA/en unknown
- 2012-07-31 WO PCT/EP2012/064970 patent/WO2013189554A1/en not_active Ceased
- 2012-07-31 AU AU2012383254A patent/AU2012383254B2/en active Active
- 2012-07-31 JP JP2015517621A patent/JP6283665B2/ja active Active
- 2012-07-31 BR BR112014031806A patent/BR112014031806A8/pt not_active Application Discontinuation
-
2014
- 2014-02-18 US US14/182,776 patent/US10294305B2/en active Active
- 2014-10-31 ZA ZA2014/07961A patent/ZA201407961B/en unknown
- 2014-11-13 IL IL235696A patent/IL235696A0/en unknown
-
2017
- 2017-09-11 US US15/700,538 patent/US11447565B2/en active Active
-
2019
- 2019-04-04 US US16/375,022 patent/US20200055953A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/933,295 patent/US20230340148A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521607A5 (enExample) | ||
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2015527318A5 (enExample) | ||
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| JP2012102122A5 (enExample) | ||
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| JP2019517549A5 (enExample) | ||
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| JP2016539122A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| NZ582619A (en) | Humanized anti-fgf19 antagonists and methods using same | |
| JP2013541583A5 (enExample) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| JP2018512402A5 (enExample) | ||
| NZ720273A (en) | Preparations and methods for treating a gd2 positive cancer | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| EA202090558A1 (ru) | Схемы лечения | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| RU2014128528A (ru) | Лечение диабета I и II типа |